Ludwig Hantson’s first full year running Alexion $ALXN in 2018 came with a bump in compensation as analysts provided some general applause for the biotech’s advances over the course of the year.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,